Hong Jin

This inventor holds 24 USPTO granted patents and 13 published patent applications, plus 5 CIPO patents and 10 EPO patents, primarily in Influenza Virus Research. Top assignees: Medimmune Limited, Medimmune Vaccines, Inc., University of Kansas. Active years: 2004-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hong Jin. Retrieved from https://idiyas.com/inventor/hong-jin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 13)

% Patents Active = 33.3

CIPO Patents = 5 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 10)

Average Co-Inventor Count = 2.7

ph-index = 9

Forward Citations = 215(Granted Patents)

Location History:

Sunnyvale, CA (US) (2007 - 2008)
Bartlesville, OK (US) (2008)
Cupertino, CA (US) (2004 - 2016)
Gaithersburg, MD (US) (2019 - 2022)

Company Filing History:

Medimmune Vaccines, Inc.

Years Active: 2004-2022

Loading Chart...

Areas of Expertise:

Influenza Virus

Hemagglutinin Variants

Neuraminidase

Multi Plasmid System

Neoplasia Treatment

Respiratory Syncytial Virus

Vaccine Development

Catalytic Hydroformylation

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11471499 - Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia (2022-10-18),

2. 10519426 - Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia (2019-12-31),

3. 9238825 - Multi plasmid system for the production of influenza virus (2016-01-19),

4. 9119812 - Influenza hemagglutinin and neuraminidase variants (2015-09-01),

5. 9068986 - Influenza B viruses having alterations in the hemagglutinin polypeptide (2015-06-30),

6. 9017694 - Swine influenza hemagglutinin variants (2015-04-28),

7. 8722059 - Multi plasmid system for the production of influenza virus (2014-05-13),

8. 8715691 - Swine influenza hemagglutinin variants (2014-05-06),

9. 8673613 - Influenza B viruses having alterations in the hemaglutinin polypeptide (2014-03-18),

10. 8613935 - Influenza hemagglutinin and neuraminidase variants (2013-12-24),

11. 8574591 - Multi plasmid system for the production of influenza virus (2013-11-05),

12. 8354114 - Multi plasmid system for the production of influenza virus (2013-01-15),

13. 8163530 - Nucleic acids encoding respiratory syncytial virus subgroup B strain 9320 (2012-04-24),

14. 8114415 - Method for producing temperature sensitive influenza A viruses (2012-02-14),

15. 8097459 - Methods and compositions for increasing replication capacity of an influenza virus (2012-01-17),

Title: Innovations by Hong Jin: Pioneering Cancer Treatment Solutions

Introduction

Hong Jin, based in Cupertino, CA, is an accomplished inventor who holds an impressive total of 23 patents. His work primarily focuses on innovative methods for treating neoplasia, showcasing his contributions to the field of medical research and therapy.

Latest Patents

Among his latest patents is a groundbreaking invention that features compositions using an attenuated Newcastle disease virus. This invention presents methods for inducing tumor regression in human subjects. The method utilizes a modified mesogenic strain of the Newcastle disease virus (NDV) with a modified F protein cleavage site. This strain is non-pathogenic to poultry, classified as lentogenic, yet it demonstrates oncolytic properties. The innovative methods proposed by Jin offer safe, effective, and reliable ways to induce tumor regression, addressing the limitations related to the usage of pathogenic virus strains in human therapy.

Career Highlights

Throughout his career, Hong Jin has contributed significantly to the field of immunology and cancer treatment. He has held key positions in reputable companies, including MedImmune Limited and MedImmune Vaccines, Inc. His expertise in virology and therapeutic innovations has made a profound impact on developing cancer therapies.

Collaborations

Hong Jin has worked alongside notable colleagues, including Zhongying Chen and Bin Lu. These collaborations have further enhanced his ability to conduct pioneering research and develop state-of-the-art therapies that harness the potential of oncolytic viruses for treating cancer.

Conclusion

Hong Jin exemplifies the spirit of innovation in the field of medical research. With a robust patent portfolio and significant collaborations, he continues to push the boundaries of traditional cancer treatment, developing safe and effective solutions for patients in need. His contributions emphasize the importance of research and innovation in overcoming medical challenges.

Profile summary based on public USPTO records.